drugset
drugset / Trial / NCT03259425

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

NCT03259425 ↗

Phase 2 Terminated 7 enrolled University of Utah Bristol-Myers Squibb · collabTakara Bio Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open label, Phase II study evaluating the safety and efficacy of neoadjuvant Nivolumab and HF10 in resectable stage IIIB, IIIC, and IVM1a melanoma.

Timeline

Start
2018-01-03
Primary completion
2018-09-21
Completion
2020-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject CANERPATUREV Other / unclassified 5 ml Other
Subject Nivolumab Monoclonal antibody 480 mg Intravenous

Indications

melanoma